伊立替康联合替吉奥二线治疗晚期胃癌的临床观察

Clinical study of irinotecan combined with S- 1 as second- line treatment for advanced gastric cancer

目的:观察伊立替康联合替吉奥二线治疗晚期胃癌的近期疗效和毒副反应。方法:27例晚期胃癌患者采用伊立替康270mg/m2,静脉滴注,第1天;替吉奥60mg/m2,分早、晚两次口服,第1-14天,21天为一个周期。结果:26例可评价疗效,其中CR 1例,PR 8例,SD 8例,有效率34.6%,疾病控制率65.4%。常见毒副反应主要有恶心、呕吐、乏力、骨髓抑制、腹泻等,但多为I/II度。结论:伊立替康联合替吉奥二线治疗晚期胃癌近期疗效较好,毒副反应可耐受。

To observe the short - term effects and adverse reactions of irinotecan combined with S - 1 as secongd - line treatment for advanced gastric cancer. Methods：Irinotecan was administered iv（270mg/ m2 ）on day 1,while S - 1 was administered orally[60mg/（m2 ·day）,bid]for 14 days followed by a 7 - day rest. This schedule was repeated every 3 weeks. Results：All 26 patients were evaluable,1 patient reached complete response（CR）,8 partial responses（PR）,8 stable disease. The overall response rate was 34. 6% ,disease control rate was 65. 4% . The major adverse effects were nausea and vomiting,fatigue,hematological,diarrhea. Conclusion：Irinotecan combined with S - 1 shows good efficacy as second - line in treatment for advanced gastric cancer. The quality of life can be im-proved and the toxicity is tolerable.